Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

Phase 4

Completed

• Conditions: Overactive Bladder; Urinary Incontinence; Quality of Life

• Registration Number: NCT00224146
• Lead Sponsor: Watson Pharmaceuticals

Brief Summary

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Detailed Description

Not available

Study Timeline

• Study Start: 2004-05
• Primary Completion: 2005-05
• Study Completion: 2005-05
• Study First Submitted: 2005-09-14
• Study First Submitted QC: 2005-09-14
• Study First Posted: 2005-09-22
• Status Verified: 2011-11
• Last Update Submitted: 2011-11-29
• Last Update Posted: 2011-11-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2878

Inclusion Criteria

• Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

Exclusion Criteria

• Patients for whom Oxytrol(r) is contraindicated.
• Patients treated with Oxytrol(r) prior to participation in this study.
• Patients residing in long-term care facilities or nursing homes.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in health-related quality of life

Secondary Outcome Measures

Name	Time	Method
Change in other outcomes such as:
depression
work productivity
participant satisfaction
effect of enhanced patient education on any of the above outcomes